Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, was honored as one of the “Top 25 Biotech & Life Sciences Companies for 2025” by The Healthcare Technology Report. This award is highly regarded by corporate executives, institutional investors, and industry leaders, cementing Immunis’ reputation as a groundbreaking force in biomedical innovation.
The Healthcare Technology Report (HTR) is a respected market research firm that reports on the developments, corporate actions, investment activity, and executive insights related to the healthcare industry. Awardees are chosen following an intensive evaluation of product innovation, leadership, strategic impact, and contributions to the global advancement of patient healthcare. Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans. Not only does Immunis have the most clinically advanced secretome therapy in the world, but it is also tackling one of the most challenging health issues for which there is no pharmaceutical cure.
Impressively, Immunis is recognized alongside some of the industry’s most influential biotech companies that are invoking actionable change in human healthcare. The coveted distinction inspires Immunis to continue revolutionizing patient-centered biotechnology and dismantling barriers towards its progress.
Comments powered by CComment